Bazedoxifene is a selective estrogen receptor modulator (SERM) used to treat moderate to severe vasomotor symptoms in menopause and osteoporosis alone or in combination with conjugated estrogens. Bazedoxifene is a third generation selective estrogen receptor modulator (SERM), developed by Pfizer following the completion of their takeover of Wyeth Pharmaceuticals.
- Mechanism
- Curator reviewed
Bazedoxifene belongs to a class of compounds known as selective estrogen receptor modulators (SERMs). Bazedoxifene acts as both an oestrogen-receptor agonist and/or antagonist, depending upon the cell and tissue type and target genes. Bazedoxifene decreases bone resorption and reduces biochemical markers of bone turnover to the premenopausal range. These effects on bone remodelling lead to an increase in bone mineral density (BMD), which in turn contributes to a reduction in the risk of fractures. Bazedoxifene functions primarily as an oestrogen-receptor antagonist in uterine and breast tissues.
- Primary indication
- Indicated for following conditions alone or in combination with conjugated estrogens in women with a uterus: Treatment of moderate to severe vasomotor symptoms associated with menopause Prevention of postmenopausal osteoporosisCurator reviewed · 3 structured indications
- Formula / weight
- C30H34N2O3 · 470.613 g/mol (avg)
- First approval
- Canada, 2014 · United States, 2013 · European Union, 2016
- Code names
- TSE-424 · WAY-140424 · WAY-TSE-424
- Brand names
Resolves to
UCJGJABZCDBEDK-UHFFFAOYSA-NSMILESCC1=C(N(CC2=CC=C(OCCN3CCCCCC3)C=C2)C2=C1C=C(O)C=C2)C1=CC=C(O)C=C1What you can answer from here — as of September 23, 2026
Which drugs share a target with Bazedoxifene, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account